First dose of potential new medicines to humans: how animals help

作者: Peter Greaves , Andrew Williams , Malcolm Eve

DOI: 10.1038/NRD1329

关键词: MEDLINEGovernmentResearch designClinical trialAlternative medicineEngineering ethicsScientific evidenceDirectiveEuropean unionMedicine

摘要: The need for careful testing of new drugs in animal models before study humans has been recognised by physicians since the First World War. Now, first human studies on are subject to detailed government guidelines, which European Union presently being reinforced through wide-ranging Clinical Trials Directive. However, despite their long history and widespread application, these guidelines empirical have formulated with a paucity critical scientific evidence. Here, we review principles available, albeit limited, evidence that support design conduct preclinical way permits effective safe first-dose potential medicines humans.

参考文章(47)
Schmidt Lh, Freireich Ej, Skipper He, Gehan Ea, Rall Dp, Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer chemotherapy reports. ,vol. 50, pp. 219- 244 ,(1966)
M. L'e. Orme, Animal Toxicity Studies: Their Relevance for Man British Journal of Clinical Pharmacology. ,vol. 31, pp. 494- ,(1991)
S Marsoni, C K Grieshaber, Relation of preclinical toxicology to findings in early clinical trials. Cancer treatment reports. ,vol. 70, pp. 65- 72 ,(1986)
The significance of the Nuremberg Code. The New England Journal of Medicine. ,vol. 338, pp. 995- 996 ,(1998) , 10.1056/NEJM199804023381417
A P Fletcher, Drug Safety Tests and Subsequent Clinical Experience Journal of the Royal Society of Medicine. ,vol. 71, pp. 693- 696 ,(1978) , 10.1177/014107687807100915
Joy A. Cavagnaro, Preclinical safety evaluation of biotechnology-derived pharmaceuticals Nature Reviews Drug Discovery. ,vol. 1, pp. 469- 475 ,(2002) , 10.1038/NRD822
Jennifer B. Dressman, Comparison of Canine and Human Gastrointestinal Physiology Pharmaceutical Research. ,vol. 3, pp. 123- 131 ,(1986) , 10.1023/A:1016353705970
Karl K. Rozman, John Doull, The Role of Time as a Quantifiable Variable of Toxicity and the Experimental Conditions When Haber's c ×t Product Can Be Observed: Implications for Therapeutics Journal of Pharmacology and Experimental Therapeutics. ,vol. 296, pp. 663- 668 ,(2001)
A. M. Monr, The Role of Metabolish Studies in Drug Safety Evaluation Drug Development Communications. ,vol. 2, pp. 377- 392 ,(1976) , 10.3109/03639047609051905